Aeglea BioTherapeutics, Inc./$SYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aeglea BioTherapeutics, Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Ticker
$SYRE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
73
ISIN
US00773J2024
Website
SYRE Metrics
BasicAdvanced
$910M
-
-$3.01
2.80
-
Price and volume
Market cap
$910M
Beta
2.8
52-week high
$21.03
52-week low
$10.91
Average daily volume
513K
Financial strength
Current ratio
8.061
Quick ratio
8.04
Profitability
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-25.34%
Return on equity (TTM)
-65.82%
Valuation
Price to book
2.78
Price to tangible book (TTM)
2.78
Price to free cash flow (TTM)
-4.702
Free cash flow yield (TTM)
-21.27%
Free cash flow per share (TTM)
-320.70%
Growth
Earnings per share change (TTM)
-60.75%
3-year earnings per share growth (CAGR)
-53.91%
10-year earnings per share growth (CAGR)
-40.30%
Bulls say / Bears say
Aeglea BioTherapeutics' acquisition of Spyre Therapeutics in June 2023 has significantly bolstered its pipeline with promising antibody therapeutics targeting inflammatory bowel disease (IBD), positioning the company to capture a substantial share of the growing IBD market. (proactiveinvestors.com)
The sale of global rights to pegzilarginase to Immedica Pharma AB in July 2023 provided Aeglea with $15 million upfront and potential milestone payments up to $100 million, enhancing its financial position to support ongoing and future projects. (marketscreener.com)
Analyst coverage initiated by Stifel in July 2023 with a 'Buy' recommendation and a significant price target increase reflects growing confidence in Aeglea's strategic direction and potential for substantial stock appreciation. (nasdaq.com)
The interim analysis of the Phase I/II study for pegtarviliase in April 2023 failed to meet its objectives, leading to a 26% stock decline and raising concerns about the efficacy of Aeglea's pipeline. (nasdaq.com)
Aeglea's decision to lay off a significant portion of its workforce in April 2023, retaining only about 10 employees, indicates financial strain and potential challenges in sustaining operations. (fiercebiotech.com)
The company's shift in focus to IBD treatments following the acquisition of Spyre Therapeutics introduces execution risks associated with entering a competitive market and developing new therapies. (proactiveinvestors.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aeglea BioTherapeutics, Inc. stock?
Aeglea BioTherapeutics, Inc. (SYRE) has a market cap of $910M as of June 20, 2025.
What is the P/E ratio for Aeglea BioTherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Aeglea BioTherapeutics, Inc. (SYRE) stock is 0 as of June 20, 2025.
Does Aeglea BioTherapeutics, Inc. stock pay dividends?
No, Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Aeglea BioTherapeutics, Inc. dividend payment date?
Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aeglea BioTherapeutics, Inc.?
Aeglea BioTherapeutics, Inc. (SYRE) has a beta rating of 2.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.